Oral treatment with Hev b 13 ameliorates experimental colitis in mice

Clinical and Experimental Immunology

Volumn 169, Issue 1, 2012, Pages 27-32

  Teixeira, L B ^a   Epifanio V L A A ^a   Lachat, J J ^a   Foss, N T ^a   Coutinho Netto, J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Colitis; Hev b 13; Interleukin 10; Mice; Trinitrobenzene sulphonic acid

Indexed keywords

ALLERGEN; HEV B 13 ALLERGEN; INTERLEUKIN 10; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DESCENDING COLON; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HEVEA BRASILIENSIS; HISTOPATHOLOGY; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM PROLAPSE; STOMACH MUCOSA LESION; TREATMENT DURATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, PLANT; COLITIS; COLON; CROHN DISEASE; DIARRHEA; FEMALE; HUMANS; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; PLANT PROTEINS; RECTAL PROLAPSE; TRINITROBENZENESULFONIC ACID; WEIGHT LOSS;

EID: 84861748540     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04589.x     Document Type: Article

References (24)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205.
2. Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010; 8:564-77.
3. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3:81-92.
4. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117:514-21.
5. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182:1281-90.
6. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20:495-549.
7. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117:1078-88.
8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369:1641-57.
9. Arif SA, Hamilton RG, Yusof F etal. Isolation and characterization of the early nodule-specific protein homologue (Hev b 13), an allergenic lipolytic esterase from Hevea brasiliensis latex. J Biol Chem 2004; 279:23933-41.
10. Palosuo T, Lehto M, Kotovuori A etal. Latex allergy: low prevalence of immunoglobulin E to highly purified proteins Hev b 2 and Hev b 13. Clin Exp Allergy 2007; 37:1502-11.
11. Teixeira LB, Pitz HS, Epifânio VLAA, Lachat JJ, Foss NT, Coutinho-Netto J. Allergenic esterase Hev b 13 induces interleukin-10 release by human mononuclear cells. Phytochemistry (in press).
12. Kuhn R, Lohler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
13. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukoc Biol 1997; 61:389-96.
14. Meresse B, Rutgeerts P, Malchow H etal. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut 2002; 50:25-8.
15. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-44.
16. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996; 39:836-45.
17. Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383-9.
18. Tomoyose M, Mitsuyama K, Ishida H, Toyonaga A, Tanikawa K. Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand J Gastroenterol 1998; 33:435-40.
19. Steidler L, Hans W, Schotte L etal. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289:1352-5.
20. Sasaki M, Mathis JM, Jennings MH etal. Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J Inflamm (Lond) 2005; 2:1476-92.
21. Braat H, Rottiers P, Hommes DW etal. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:754-9.
22. Fichtner-Feigl S, Fuss IJ, Young CA etal. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2, 4, 6-trinitrobenzene sulfonic acid colitis. J Immunol 2007; 178:5859-70.
23. Rougé P, Culerrier R, Campistron M etal. Allergenicity of Hev b 13, a major esterase allergen in natural rubber latex (Hevea brasiliensis) allergy, does not only depend on its carbohydrate moiety. Mol Immunol 2010; 47:871-7.
24. Siccardi D, Turner JR, Mrsny RJ. Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57:219-35.